INS and type 2 diabetes mellitus: The study aimed to understand the impact of adding the traditional antidiabetic drug metformin and the novel antidiabetic drug dapagliflozin to routine intensive insulin therapy on treatment outcomes.<h4>Methods</h4>A total of 110 patients with newly diagnosed T2DM (with glycated hemoglobin >9%, fasting blood glucose >11.1 mmol/L, or obvious symptoms of hyperglycemia) were enrolled in a single-center randomized controlled trial.